Literature DB >> 6819082

The effects of cyclophosphamide on in vitro cytotoxic responses to a syngeneic tumour.

E J Hancock, D G Kilburn.   

Abstract

We have studied the effects of treating DBA/2 mice with high doses of cyclophosphamide upon their subsequent ability to generate cytotoxic cells in vitro against syngeneic tumour antigens or alloantigens. High doses of cyclophosphamide (100-200 mg/kg body weight) eliminated the response to both antigens. The addition of normal DBA/2 thymocytes into these cultures restored the response to allogeneic cells but not to tumour cells. The anti-tumour response could be restored by the addition of interleukin 2 to the cultures. Treatment with high doses of cyclophosphamide decreased the number of anti-tumour cytotoxic cell precursors in the spleen, but did not affect the capacity of bulk cultures of spleen cells to produce interleukin 2 when stimulated with the mitogen concanavalin A.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6819082     DOI: 10.1007/bf00199433

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Quantitative studies on the precursors of cytotoxic lymphocytes. I. Characterization of a clonal assay and determination of the size of clones derived from single precursors.

Authors:  H S Teh; E Harley; R A Phillips; R G Miller
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

2.  Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide.

Authors:  J L Turk; D Parker; L W Poulter
Journal:  Immunology       Date:  1972-10       Impact factor: 7.397

3.  Differential effects of cyclophosphamide on the B and T cell compartments of adult mice.

Authors:  G D Stockman; L R Heim; M A South; J J Trentin
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

4.  Helper cells active in the generation of cytotoxicity to a syngeneic tumor.

Authors:  E J Hancock; D G Kilburn; J G Levy
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

Review 5.  Cyclophosphamide: use in practice.

Authors:  M E Gershwin; E J Goetzl; A D Steinberg
Journal:  Ann Intern Med       Date:  1974-04       Impact factor: 25.391

6.  Antigen-induced cyclophosphamide-resistant suppressor T cells inhibit the in vitro generation of cytotoxic cells from one-way mixed leukocyte reactions.

Authors:  B Bonavida
Journal:  J Immunol       Date:  1977-10       Impact factor: 5.422

7.  T-T-cell interactions during the vitro cytotoxic allograft responses. I. Soluble products from activated Lyl+ T cells trigger autonomously antigen-primed Ly23+ T cells to cell proliferation and cytolytic activity.

Authors:  H Wagner; M Röllinghoff
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

8.  Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice.

Authors:  M Glaser
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

9.  A requirement for antigen-specific helper T cells in the generation of cytotoxic T cells from thymocyte precursors.

Authors:  L M Pilarski
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

10.  Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

Authors:  P W Askenase; B J Hayden; R K Gershon
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

View more
  8 in total

1.  Immunoregulatory cytokine release in rat spleen cell cultures after treatment with bleomycin and its analogues in vivo.

Authors:  M Micallef; M Hosokawa; T Shibata; A Nakane; Z B Yang; T Minagawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Enhancement of interleukin-2 release in rats by treatment with bleomycin and adriamycin in vivo.

Authors:  T A Abdul Hamied; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity.

Authors:  S K Hoover; S K Barrett; T M Turk; T C Lee; H D Bear
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Rescue of anti-influenza A virus cytotoxic T-lymphocyte responses in chemotherapy-suppressed mice.

Authors:  V J Merluzzi; K Welte; R H Mertelsmann; L Souza; T Boone; K Last-Barney
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

5.  The use of cytotoxic T cells in the regulation of tumour growth in syngeneic mice.

Authors:  L Kwong; D G Kilburn; H S Teh
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice.

Authors:  H Shindo; T Ogura; T Masuno; S Hayashi; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets.

Authors:  S Peppoloni; B J Mathieson; R B Herberman; R W Overton; E Gorelik
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Cyclophosphamide-dependent lymph node modification in lymph node metastasis of MM48 tumor cells in syngeneic mice.

Authors:  K Yoshida; T Tachibana
Journal:  Jpn J Cancer Res       Date:  1990-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.